TON - January/February 2014 Vol 7 No 1

Advances in breast cancer diagnostics and treatment have led to improved survival for patients with breast cancer. However, survivors still face psychosocial and physical challenges. Read More ›

For the first-line treatment of HER2-positive metastatic breast cancer, the combination of eribulin mesylate and trastuzumab yields higher response rates, with manageable toxicity. Read More ›

Data from a large population of patients with multiple myeloma receiving zoledronic acid infusions indicate that osteonecrosis of the jaw (ONJ) remains a significant complication, especially for patients who receive it for prolonged periods, investigators from Greece reported at the 2013 American Society of Hematology annual meeting. Read More ›

NEPA, a fixed-dose combination of netupitant and palonosetron, proved more effective than palonosetron alone in preventing chemotherapy-induced nausea and vomiting (CINV) in a large multinational study of 1455 patients, according to data presented at the 2013 San Antonio Breast Cancer Symposium. Read More ›

The majority of hereditary cancer syndromes are inherited in an autosomal dominant fashion. Thus, offspring have a 50% chance of inheriting the condition, as well as a 50% chance of not inheriting it. Read More ›

Management of ductal carcinoma in situ (DCIS) was the focus of 2 studies highlighted at a premeeting Press Cast for the American Society of Clinical Oncology Breast Cancer Symposium held in San Francisco, California. Read More ›

Welcome to the first issue of The Oncology Nurse-APN/PA (TON) for 2014. We’re looking forward to a year of keeping you up-to-date about what is happening in the world of oncology research and bringing you information that helps you in your day-to-day practice as a healthcare professional. Read More ›

Page 2 of 2


Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: